Roche posts 7-percent rise in fourth-quarter diagnostics sales

Headline results for the fourth quarter:

Diagnostics division sales

3.5 billion francs ($3.5 billion)

+7%

Revenue

14.8 billion francs ($14.9 billion)

+6%

Note: All changes are versus the prior-year period unless otherwise stated

What the company said:

"Roche achieved very good growth in both divisions," CEO Severin Schwan remarked, adding that the company "is also making major progress in driving digitalisation, and in leveraging real-world healthcare data and analytics to support product development and advance personalised healthcare."

Other results:

  • Centralised and Point of Care Solutions: 2.1 billion francs ($2.1 billion), up 9 percent, led by growth in the immunodiagnostics business
  • Molecular Diagnostics: 551 million francs ($555 million), up 4 percent
  • Diabetes care: 496 million francs ($500 million), down 1 percent
  • Tissue Diagnostics: 311 million francs ($313 million), up 11 percent
  • Full-year diagnostics division sales: 12.9 billion francs ($13 billion), up 7 percent
  • Full-year revenue: 56.8 billion francs ($57.2 billion), up 7 percent, above forecasts of 56.4 billion francs ($56.8 billion)
  • Full-year profit: 10.9 billion francs ($11 billion), up 23 percent

Looking ahead:

Roche expects revenue this year to grow in the low- to mid-single digit range, at constant exchange rates, with core earnings per share targeted to grow "broadly in line" with sales, at constant exchange rates.

Did you like this article?